Status:

COMPLETED

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

Lead Sponsor:

Asan Medical Center

Collaborating Sponsors:

Janssen Korea, Ltd., Korea

Conditions:

Lymphoma, Large-Cell, Diffuse

Lymphoma, B-Cell

Eligibility:

All Genders

15-70 years

Phase:

PHASE1

PHASE2

Brief Summary

Diffuse large B-cell lymphoma is a most prevalent non-Hodgkin's lymphoma. Recently the clinical results have been improved with new drugs and new modalities such as cyclophosphamide, doxorubicin, vinc...

Detailed Description

Intended number of patients: 63 patients in total * Phase I: 9 patients for 3 levels * Phase II: 50 patients plus 3 patient from Phase I at MTD level * Plus 4 patients: considering 5% follow-up loss ...

Eligibility Criteria

Inclusion

  • Histologically confirmed DLBCL
  • Age 70 years or less
  • Previously untreated
  • Performance status: ECOG 0-2
  • Advanced stage: stage III, IV, or non-contiguous stage II
  • Measurable disease: 1 cm or more by spiral CT
  • Normal liver function

Exclusion

  • Platelet count less than 75,000/microL within 14 days before enrollment.
  • Absolute neutrophil count of less than 1,500/microlL within 14 days before enrollment.
  • Cr more than 2.0 mg/dL and/or calculated or measured creatinine clearance less than 50 mL/min within 14 days before enrollment.
  • Peripheral neuropathy of Grade 2 or worse within 14 days before enrollment.
  • Hypersensitivity to bortezomib, boron or mannitol.
  • Female subject is pregnant or breast-feeding.
  • Other investigational drugs with 14 days before enrollment
  • Serious medical or psychiatric illness likely to interfere with participation in this clinical study.
  • Uncontrolled or severe cardiovascular disease, including MI within 6 months of enrolment, New York Heart Association (NYHA) Class III or IV heart failure, uncontrolled angina, clinically significant pericardial disease, or cardiac amyloidosis

Key Trial Info

Start Date :

September 1 2006

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

January 1 2011

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT00379574

Start Date

September 1 2006

End Date

January 1 2011

Last Update

March 15 2013

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Asan Medical Center, University of Ulsan College of Medicine

Seoul, South Korea, 138-736

2

Asan Medical Cener

Seoul, South Korea

Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL | DecenTrialz